At the core of Fortress Biotech is a business development engine that is designed to build our product portfolio. We are interested in new drug candidates in all phases of development, as well as marketed products. We are also interested in specialty pharmaceuticals, repurposed drugs and generic products, including alternate delivery forms of previously-approved products, whether in development or on the market. Fortress Biotech is agnostic to therapeutic area and we have already executed agreements in the following therapeutic areas: oncology, pain management, dermatology and autoimmune diseases.
We pride ourselves on accelerated evaluation of opportunities and deal consummation. Fortress Biotech, Inc. is flexible with deal-structuring including conventional licensing, equity arrangements, joint ventures, option agreements and others. Additionally, many entrepreneurs and Universities are interested in forming a new company around their inventions. We have formed many new companies specifically to advance the development of the drugs to which we acquire rights and we utilize our strong balance sheet to provide initial capital for these companies. We will leverage our relationships on Wall Street to raise additional capital for some of the Fortress Companies. Ultimately, we expect many of these Fortress Companies will be spun-out as public companies or may be acquired or partner with larger pharmaceutical companies to advance their products.
Finally, under certain circumstances, we may make controlling investments in companies with proprietary products and/or technologies where we believe shareholder value will be enhanced, while preserving capital and the strength of our balance sheet.